20130367.TNBC
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- INTERFERON_ALPHA_RESPONSE+0.400
- E2F_TARGETS+0.340
- HYPOXIA+0.340
- WNT_BETA_CATENIN_SIGNALING+0.330
- GLYCOLYSIS+0.320
- APICAL_JUNCTION+0.310
- APICAL_SURFACE+0.300
- COAGULATION+0.260
- G2M_CHECKPOINT+0.260
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.240
- ALLOGRAFT_REJECTION-0.230
- BILE_ACID_METABOLISM-0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.200
- PANCREAS_BETA_CELLS-0.180
- FATTY_ACID_METABOLISM-0.160
- PEROXISOME-0.160
- CHOLESTEROL_HOMEOSTASIS-0.100
- ESTROGEN_RESPONSE_LATE-0.090
- ADIPOGENESIS-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0WA-01A-11R-A109-07 | — | E | 0.739 |
| 2 | SRR650184 | — | — | 0.734 |
| 3 | TCGA-85-8582-01A-21R-2403-07 | — | cohortSQ1 | 0.731 |
| 4 | SRR650185 | — | — | 0.730 |
| 5 | TCGA-D8-A13Z-01A-11R-A115-07 | — | C | 0.727 |
| 6 | TCGA-FD-A62S-01A-11R-A30C-07 | — | — | 0.726 |
| 7 | TCGA-CV-6950-01A-11R-1915-07 | — | — | 0.720 |
| 8 | TCGA-77-8136-01A-11R-2247-07 | — | cohortSQ1 | 0.707 |
| 9 | TCGA-EW-A1OW-01A-21R-A144-07 | — | E | 0.707 |
| 10 | TCGA-CN-5363-01A-01R-1436-07 | — | — | 0.706 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.340 | Inavolisib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.330 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.320 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.310 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.240 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| COMPLEMENT | 0.160 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.140 | Idelalisib | — uncovered |